Filing Flows

Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Next earnings date

Tonix Pharmaceuticals Holding (TNXP) earnings on Nov 9, 2026: what to expect

Tonix Pharmaceuticals Holding (TNXP) is expected to report earnings on Nov 9, 2026, tomorrow, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$2.24 (−$2.40 to −$2.15, 3 estimates) on revenue of $16.3M, against −$3.70 and $3.3M a year ago. It beat the EPS estimate in 25% of the quarters on record; Filing Flows' model gives it a 52% chance of beating next time.

Report dateNov 9, 2026
Days to go1
EPS estimate−$2.24
Revenue estimate$16.3M
Beat rate25%

What to watch

Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:

Tonix Pharmaceuticals Holding: revenue lines, growth year over year, Q2 2026Tonix Pharmaceuticals Holding: revenue lines, growth year over year, Q2 2026Revenue+578%Zembrace Symtouch+27%Tosymra+39%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$3.70 on revenue of $8.4M, against the analysts' −$2.24.

The last report

Tonix Pharmaceuticals Holding reported revenue of $13.5M for the second quarter 2026 (+578% Y/Y), net loss $40.6M: Tonmya $11.0M, Zembrace Symtouch $2.0M, Tosymra $594K. How it makes money → · Every quarter →

Tonix Pharmaceuticals Holding: EPS against the estimate, last 4 reportsTonix Pharmaceuticals Holding: EPS against the estimate, last 4 reportsEstimateReported−$2.75−$3.70Nov 25−$2.94−$3.98Mar 26−$2.54−$2.93May 26−$2.62−$2.47Aug 26
Latest (Aug 26): Estimate −$2.62, Reported −$2.47.

Tonix Pharmaceuticals Holding's latest quarter

Tonix Pharmaceuticals Holding, Q2 2026: revenue $13.5M (+578% year over year), operating margin -314.1%, net loss $40.6M, operating cash flow −$42.2M. The chart follows the revenue to costs, profit and cash.

Questions

When does TNXP report earnings?

Tonix Pharmaceuticals Holding is expected to report on Nov 9, 2026.

What are analysts expecting from Tonix Pharmaceuticals Holding?

EPS of −$2.24 and revenue of $16.3M for the quarter.

Does Tonix Pharmaceuticals Holding usually beat earnings?

It beat the consensus EPS estimate in 25% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.